Amgen
Corporate Headquarters
One Amgen Center Drive
Thousand Oaks
California
91320-1799
United States
Tel: 805-447-1000
Fax: 805-447-1010
Website: http://www.amgen.com/
About Amgen
At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.
We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.
As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.
At Amgen, we believe in the power of tomorrow and it shows.
Discover what Amgen can do for you by visiting careers.amgen.com.
For more information, visit
www.amgen.com, LinkedIn and follow us on www.twitter.com/amgencareers.
FOLLOW AMGEN:
Tweets by Amgen
The Amgen Difference
1835 articles with Amgen
-
With more than 82,500 employees working in the sector, California’s Bay Area is one of the strongest homes for biotech companies in the world.
-
Amgen continues to move toward completing its promise of shifting patients to a cheaper cost of its blockbuster anti-cholesterol drug Repatha, a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor.
-
Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price
1/7/2019
The Repatha Pre-Filled Syringe and Repatha Pushtronex® System are Now Available at a Reduced List Price of $5,850
-
Teva and Amgen Resolve Ongoing Dispute Over Teva’s Generic Cinacalet HCl Product
1/3/2019
Teva Pharmaceutical Industries Ltd. announced today that it has resolved its ongoing dispute with Amgen over Teva’s generic cinacalcet HCl product.
-
Amgen To Present At The 37th Annual J.P. Morgan Healthcare Conference
1/3/2019
Amgen will present at the 37th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 8, 2019, in San Francisco. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference.
-
With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.
-
An analysis shows that more than 30 drugmakers plan to increase the price of prescription medicine in January, despite presidential rhetoric.
-
Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology
12/19/2018
Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin® Molecule, in Combination with Amgen's Oncology Assets, Including BiTE® Molecules
-
Amgen Submits Supplemental Biologics License Application For Nplate® (romiplostim)
12/19/2018
Amgen (NASDAQ:AMGN) today announced the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Nplate® (romiplostim) to include the treatment of adult patients with immune thrombocytopenia (ITP) who have had ITP for 12 months or less and an insufficient response to corticosteroids, immunoglobulins or splenectomy.
-
Amgen Engages Cambridge Biotech Community To Select 2018 LabCentral Golden Ticket Winners
12/18/2018
Amgen Golden Tickets Provide Startup Companies With Free Lab Space to Further Advance Innovative Science and Technology
-
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
12/17/2018
Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE® (infliximab).
-
FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
12/14/2018
Approval Based on Results That Demonstrated Nplate Successfully Increased and Sustained Platelet Counts in Children Affected by Rare Blood Disorder
-
Shares of New Jersey-based Advaxis have plunged more than 28 percent in premarket trading after the company quietly disclosed that Amgen terminated its collaboration on an immuno-oncology program. The deal between the two companies was first inked in 2016 and had a value of up to $540 million.
-
deCODE Genetics, An Amgen Subsidiary, And SomaLogic Announce Collaboration To Perform Large-Scale Protein Analysis Of Up To 40,000 Human Samples
12/13/2018
Largest-ever Protein Measurement Study Enhances deCODE's Efforts in Basic Research, Drug Discovery and Novel Protein-based Diagnostics
-
Amgen And Direct Relief Partner To Aid Cancer Patients In 18 Developing Countries
12/13/2018
Amgen Donates $93 Million Worth of Cancer Medicines
-
White Americans make up the vast majority of clinical trial participants, despite evidence that some cancers affect minority populations in greater numbers.
-
Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions
12/11/2018
Amgen (NASDAQ:AMGN) today announced a novel multi-year collaboration with Magellan Rx Management, the pharmacy benefit management division of Magellan Health, that will leverage each company's capabilities and resources to identify clinical gaps for some of the healthcare system's most difficult-to-treat diseases
-
Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials
12/10/2018
Amgen (NASDAQ:AMGN) and the Lazarex Cancer Foundation, a non-profit organization focused on improving patient access to cancer clinical trials, today announced that they have teamed up to support more equitable access to clinical trials for cancer patients in the U.S.
-
Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend
12/7/2018
Amgen today announced that its Board of Directors declared a $1.45 per share dividend for the first quarter of 2019.
-
Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018
12/4/2018
Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia